|
Breast Carcinoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
28/130 (21.5%) breast cancer cases showed promoter hypermethylation with reduced CAV-1 expression levels when compared with adjacent normal breast tissue.
|
22502704 |
2012 |
|
Breast Carcinoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Breast cancer nodal metastasis correlates with tumour and lymph node methylation profiles of Caveolin-1 and CXCR4.
|
24590865 |
2014 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells.
|
11948420 |
2002 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia.
|
12368209 |
2002 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status.
|
16723714 |
2006 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Caveolin-1 up-regulates IGF-I receptor gene transcription in breast cancer cells via Sp1- and p53-dependent pathways.
|
17014845 |
2006 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Caveolin-1 was identified in a screen for genes involved in breast cancer progression and we demonstrated 29.2% mutational status in our Kashmiri ethnic population.
|
21133631 |
2010 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Caveolin-1-containing extracellular vesicles transport adhesion proteins and promote malignancy in breast cancer cell lines.
|
30338706 |
2018 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A panel of nonfunctional and p53-deficient colon and epithelial breast cancer cell lines showed undetectable expression of Cav-1 supporting the role of p53 in the control of Cav-1.
|
23114650 |
2013 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Accordingly, we have suggested that Cav-1 may be a predictive biomarker for breast cancer.
|
28236153 |
2018 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
As loss of Cav-1 is a stromal marker of poor clinical outcome in women with primary breast cancer, dissecting the downstream signaling effects of Cav-1 are important for understanding disease pathogenesis, and identifying novel therapeutic targets.
|
22684333 |
2012 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Based on current research, this review presents the current understanding of their function and the involvement of caveolin-1 in breast cancer pathogenesis.
|
22353223 |
2011 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Because oxytocin receptor localization within caveolin-1-enriched membrane domains is necessary for activation of the proliferative (instead of the inhibitory) response to oxytocin, its enhanced expression can be involved in the oxytocin-induced B-TEC growth as well.
|
16778082 |
2006 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Besides, it has been reported that the loss of stromal Cav-1 might predict poor prognosis in breast cancer, gastric cancer, pancreas cancer, prostate cancer, oral SCC and esophageal SCC.
|
28243118 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clinical investigation also revealed a close correlation between caveolin-1 and β-catenin/ABCG2 signaling in breast cancer samples.
|
25085904 |
2014 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Consequently, a meta-analysis to evaluate and summarize the association of the CAV1 polymorphisms with breast cancer susceptibility.
|
31303379 |
2019 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Consistent with our observations in the breast cancer cell lines, expression of Caveolin-1 identified a subset of basal breast cancers, particularly of metaplastic pathology, and only 50 % of these lacked E-cadherin expression.
|
23338761 |
2013 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Correction: Mechanosensitive caveolin-1 activation-induced PI3K/Akt/mTOR signaling pathway promotes breast cancer motility, invadopodia formation and metastasis <i>in vivo</i>.
|
30220978 |
2018 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization.
|
21501481 |
2011 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dose-response studies showed that the growth inhibition seen at lower concentrations of CDDO correlated with induction of the tumor suppressor gene caveolin-1, which is known to inhibit breast cancer cell growth.
|
16505105 |
2006 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Enrichment analysis and experimental validation demonstrated that ADQ might improve breast cancer chemosensitivity <i>via</i> inhibiting caveolin-1, which further triggered expression changes of cell cycle-related proteins p21/cyclinB1 and apoptosis-associated proteins PARP1, BAX and Bcl-2.
|
30333750 |
2018 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Finally, new roles of CAV1 in BC both on epithelium and stroma may be useful as prognostic indicators for patient treatment and help clinicians in the selection of the best personalized therapy.
|
25977173 |
2016 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Functionally, we demonstrate that fibroblasts co-cultured with MCF7 breast cancer cells acquire a cancer associated fibroblast phenotype, characterized by Cav-1 downregulation, increased expression of myofibroblast markers and extracellular matrix proteins, and constitutive activation of TGFβ/Smad2 signaling. siRNA-mediated Cav-1 downregulation mimics several key changes that occur in co-cultured fibroblasts, clearly indicating that a loss of Cav-1 is a critical initiating factor, driving stromal fibroblast activation during tumorigenesis.
|
20562526 |
2010 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Further analysis by EST vNorthern and virtual microarray analysis reduced the candidate genes to six, with four down-regulated genes, ANXA1, CAV1, KRT5 and MMP7, and two up-regulated genes, ERBB2 and G1P3 in breast cancer.
|
15647832 |
2005 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetic evidence from the study of Cav-1(-/-) null mice and human breast cancer mutations [CAV-1 (P132L)] supports the idea that caveolin-1 normally functions as a negative regulator of cell transformation and mammary tumorigenesis.
|
15692148 |
2005 |